Overview

Optimal Single Dose Intrathecal Dexmedetomidine for Postoperative Analgesia

Status:
Unknown status
Trial end date:
2017-06-01
Target enrollment:
0
Participant gender:
All
Summary
Spinal anesthesia is a commonly used technique for lower limb surgeries offering better quality of postoperative analgesia, lower incidence of side effects, and shorter post-anesthesia care unit stay than general anesthesia. However, the relatively short duration of action of the currently available local anesthetics (LAs) make these advantages short-lived. The risk for local anesthetic toxicity (LAST) increases with the trials to use higher concentrations or volumes of intrathecal local anesthetics to increase the duration of analgesia. Dexmedetomidine has the potential to prolong the duration of perioperative analgesia without the need for using high doses of local anesthetics and hence with decreasing the potential risk of local anesthetic, but the increased likelihood adverse effects such as short term bradycardia and prolonged duration of motor block may offset these benefits.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Mansoura University
Treatments:
Dexmedetomidine
Criteria
Inclusion Criteria:

- American Society of Anesthesiologists physical class I to II.

- Patients scheduled for elective lower limb surgeries.

Exclusion Criteria:

- Morbid obese patients.

- Severe or uncompensated cardiovascular disease.

- Significant renal disease.

- Significant hepatic disease.

- Pregnancy.

- Lactating .

- Heart block.

- Bradyarrhythmias.

- Receiving adrenergic receptor antagonist medications.

- Receiving calcium channel blockers.

- Patients with pacemakers.

- Patients with implanted cardioverter defibrillator.

- Allergy to the study medications.

- Psychological disease.

- Neurological disorders.

- Communication barrier.

- Mental disorders.

- Epilepsy.

- Drug or alcohol abuse.

- Contraindications to spinal anaesthesia.

- Receiving opioid analgesic medications within 24 h before the operation.